Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Manuscript
  • Published:

Timed-sequential chemotherapy with concomitant granulocyte colony-stimulating factor for newly diagnosed de novo acute myelogenous leukemia

Leukemia volume 17, pages 1078–1084 (2003)Cite this article

Abstract

EMA, consisting of etoposide, mitoxantrone, and cytarabine, is a timed-sequential chemotherapy (TSC) regimen and an efficacious option for induction treatment of acute myelogenous leukemia (AML). Hematopoietic growth factors (HGFs) have been shown to recruit leukemic blasts into cell cycle. We postulated the addition of granulocyte colony-stimulating factor (G-CSF) to EMA (EMA-G) might enhance treatment efficacy. EMA-G consisted of mitoxantrone on days 1–3, cytarabine on days 1–3 and 8–10, etoposide on days 8–10, and G-CSF from day 4 until absolute neutrophil count (ANC) >500/μl. In total, 28 patients were enrolled. All patients had newly diagnosed de novo AML. The median age was 42 years. Of the 27 patients with cytogenetic analysis, six had favorable karyotype, 18 intermediate karyotype, and three unfavorable karyotype. The median follow-up was 37.5 months. The median time for both ANC recovery and last platelet transfusion was 26 days. The toxicities associated with this regimen were no more than those expected with the standard chemotherapy. In all, 24 (86%) patients achieved complete remission (CR), three (11%) patients had no response, and one patient died within 24 h of induction therapy before response could be evaluated. Of the 24 patients who achieved CR, 22 received high-dose cytosine arabinoside and two received allogeneic bone marrow transplant as initial postremission therapy. For the whole cohort, the estimated 3-year survival rate was 67%. The median relapse-free survival was 30.5 months. We conclude that EMA-G regimen is a safe regimen and administration of G-CSF during and after induction treatment is not associated with prolongation of marrow aplasia or acceleration of leukemia relapse. It is efficacious for induction therapy for newly diagnosed de novo AML. A high CR rate can be achieved with only one course of this chemotherapy.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1

Similar content being viewed by others

References

  1. Lowenberg B, Downing JR, Burnett A . Acute myeloid leukemia. N Engl J Med 1999; 14: 1051–1062.

    Article  Google Scholar 

  2. Burnett AK . Tailoring the treatment of acute leukemia. Curr Opin Hematol 1999; 4: 247–252.

    Article  Google Scholar 

  3. Freirerich EJ . Four decades of therapy for AML. Leukemia 1998; 12 (Suppl 1): 54–56.

    Google Scholar 

  4. Burke PJ, Karp JE, Braine HG, Vaughan WP . Timed sequential therapy of human leukemia based upon the response of leukemic cells to human growth factors. Cancer Res 1977; 37: 2138–2146.

    CAS  PubMed  Google Scholar 

  5. Vaughan WP, Karp JE, Burke PJ . Long chemotherapy-free remissions after single-cycle timed-sequential chemotherapy for acute myelocytic leukemia. Cancer 1980; 45: 859–865.

    Article  CAS  PubMed  Google Scholar 

  6. Burke PJ, Karp JE, Vaughan WP, Sanford PL . Recruitment of quiescent tumor by humoral stimulatory activity: requirements for successful chemotherapy. Blood Cells 1982; 8: 519–533.

    CAS  PubMed  Google Scholar 

  7. Arlin ZA, Kempin SJ, Mertelsmann R, Gee TS, Clarkson B . Patients with secondary acute myelocytic leukemia (AML) receiving ‘timed’ sequential chemotherapy [letter]. J Clin Oncol 1983; 1: 513.

    Article  CAS  PubMed  Google Scholar 

  8. Vaughan WP, Karp JE, Burke PJ . Two-cycled timed sequential chemotherapy for adult acute nonlymphocytic leukemia. Blood 1984; 64: 975–980.

    CAS  PubMed  Google Scholar 

  9. Geller RB, Burke PJ, Karp JE, Humphrey RL, Braine HG, Tucker RW et al. A two-step timed sequential treatment for acute myelocytic leukemia. Blood 1989; 74: 1499–1506.

    CAS  PubMed  Google Scholar 

  10. Karp JE, Donehower RC, Enterline JP, Dole GB, Fox MG, Burke PJ . In vivo cell growth and pharmacologic determinants of clinical response in acute myelogenous leukemia. Blood 1989; 73: 24–30.

    CAS  PubMed  Google Scholar 

  11. Fiere D, Campos L, Van HV, Guyotat D, Archimbaud E, Extra JM et al. Intensive timed chemotherapy protocol for 37 resistant or relapsing acute myeloid leukemias. Cancer Treat Rep 1986; 70: 285–286.

    CAS  PubMed  Google Scholar 

  12. Archimbaud E, Leblond V, Michallet M, Cordonnier C, Fenaux P et al. Intensive sequential chemotherapy with mitoxantrone and continuous infusion etoposide and cytarabine for previously treated acute myelogenous leukemia. Blood 1991; 77: 1894–1900.

    CAS  PubMed  Google Scholar 

  13. Archimbaud E, Thomas X, Leblond V, Michallet M, Fenaux P, Cordonnier C et al. Timed sequential chemotherapy for previously treated patients with acute myeloid leukemia: long-term follow-up of the etoposide mitoxantrone and cytarabine-86 trial. J Clin Oncol 1995; 13: 11–18.

    Article  CAS  PubMed  Google Scholar 

  14. Archimbaud E, Leblond V, Fenaux P, Dombret H, Cordonnier C, Dreyfus F et al. Timed sequential chemotherapy for advanced acute myeloid leukemia. Hematol Cell Therapy 1996; 38: 161–167.

    Article  CAS  Google Scholar 

  15. Dombret H, Chastang C, Fenaux P, Reiffers J, Bordessoule D, Bouabdallah R et al. A controlled study of recombinant human granulocyte colony-stimulating factor in elderly patients after treatment for acute myelogenous leukemia. AML Cooperative Study Group [see comments]. New Engl J Med 1995; 332: 1678–1683.

    Article  CAS  PubMed  Google Scholar 

  16. Heil G, Hoelzer D, Sanz MA, Lechner K, Yin JAL, Papa G et al. A randomized, double-blind, placebo-controlled, phase III study of filgrastim in remission induction and consolidation therapy for adults with de novo acute myeloid leukemia. The International Acute Myeloid Leukemia Study Group. Blood 1997; 90: 4710–4718.

    CAS  PubMed  Google Scholar 

  17. Godwin JE, Kopecky KJ, Head DR, Willman CL, Leith CP, Hynes HE et al. A double-blind placebo-controlled trial of granulocyte colony-stimulating factor in elderly patients with previously untreated acute myeloid leukemia: A Southwest Oncology Group Study (9031). Blood 1998; 91: 3607–3615.

    CAS  PubMed  Google Scholar 

  18. Rowe JM, Andersen JW, Mazza JJ, Bennett JM, Paietta E, Hayes FA et al. A randomized placebo-controlled phase III study of granulocyte–macrophage colony-stimulating factor in adult patients (>55 to 70 years of age) with acute myelogenous leukemia: a study of the Eastern Cooperative Oncology Group (E1490). Blood 1995; 86: 457–462.

    CAS  PubMed  Google Scholar 

  19. Stone RM, Berg DT, George SL, Dodge RK, Paciucci PA, Schulman P et al. Granulocyte–macrophage colony-stimulating factor after initial chemotherapy for elderly patients with primary acute myelogenous leukemia. Cancer and Leukemia Group B. N Engl J Med 1995; 332: 1671–1677.

    Article  CAS  PubMed  Google Scholar 

  20. Lowenberg B, Touw IP . Hematopoietic growth factors and their receptors in acute leukemia. Blood 1993; 81: 281–292.

    CAS  PubMed  Google Scholar 

  21. Jahns-Streubel G, Reuter C, Unterhalt M, Schleyer E, Wormann B, Buchner T et al. Blast cell proliferative activity and sensitivity to GM-CSF in vitro are associated with early response to TAD-9 induction therapy in acute myeloid leukemia. Leukemia 1995; 9: 1857–1863.

    CAS  PubMed  Google Scholar 

  22. Karp JE, Burke PJ, Donehower RC . Effects of rhGM-CSF on intracellular Ara-C pharmacology in vitro in acute myelocytic leukemia: comparability with drug-induced humoral stimulatory activity. Leukemia 1990; 4: 553–556.

    CAS  PubMed  Google Scholar 

  23. Liesveld JL, Keng PC, Rowe JM, DiPersio JF, Abboud CN . Effects of GM-CSF on Ki67 expression and cell cycle traverse in acute myelogenous leukemia specimens and cell lines. Leukemia Res 1994; 18: 609–616.

    Article  CAS  Google Scholar 

  24. Smith MA, Smith JG, Pallister CJ, Singer CR . Haemopoietic growth factors, the cell cycle of acute myeloblastic leukaemia progenitors and sensitivity to cytosine arabinoside. Leukemia Lymphoma 1996; 23: 467–472.

    Article  CAS  PubMed  Google Scholar 

  25. Tanaka M . Recombinant GM-CSF modulates the metabolism of cytosine arabinoside in leukemic cells in bone marrow. Leukemia Res 1993; 17: 585–592.

    Article  CAS  Google Scholar 

  26. te Boekhorst PA, Lowenberg B, Sonneveld P . Hematopoietic growth factor stimulation and cytarabine cytotoxicity in vitro: effects in untreated and relapsed or primary refractory acute myeloid leukemia cells. Leukemia 1994; 8: 1480–1486.

    CAS  PubMed  Google Scholar 

  27. te Boekhorst PA, Lowenberg B, Vlastuin M, Sonneveld P . Enhanced chemosensitivity of clonogenic blasts from patients with acute myeloid leukemia by G-CSF IL-3 or GM-CSF stimulation. Leukemia 1993; 7: 1191–1198.

    CAS  PubMed  Google Scholar 

  28. Heil G, Chadid L, Hoelzer D, Seipelt G, Mitrou P, Huber C et al. GM-CSF in a double-blind randomized placebo controlled trial in therapy of adult patients with de novo acute myeloid leukemia (AML). Leukemia 1995; 9: 3–9.

    CAS  PubMed  Google Scholar 

  29. Lowenberg B, Boogaerts MA, Daenen SM, Verhoef GE, Hagenbeek A, Vellenga E et al. Value of different modalities of granulocyte–macrophage colony-stimulating factor applied during or after induction therapy of acute myeloid leukemia. J Clin Oncol 1997; 15: 3496–3506.

    Article  CAS  PubMed  Google Scholar 

  30. Lowenberg B, Suciu S, Archimbaud E, Ossenkoppele G, Verhoef GEG, Vellenga E et al. Use of recombinant granulocyte-macrophage colony-stimulating factor during and after remission induction chemotherapy in patients aged 61 years and older with acute myeloid leukemia (AML): final report of AML-11, a phase III randomized study of the leukemia Cooperative Group of the European Organization for the Research and Treatment of Cancer (EORTC-LCG) and the Dutch Belgian Hemato-Oncology Cooperative Group (HOVON). Blood 1977; 90: 2952–2961.

    Google Scholar 

  31. Witz F, Sadoun A, Perrin MC, Berthou C, Briere J, Cahn JY et al. A placebo-controlled study of recombinant granulocyte–macrophage colony-stimulating factor administered during and after induction treatment for de novo acute myelogenous leukemia in elderly patients. Blood 1998; 91: 2722–2730.

    CAS  PubMed  Google Scholar 

  32. Zittoun R, Suciu S, Manelli F, de Witte T, Thaler J, Stryckmans P et al. Granulocyte-macrophage colony-stimulating treatment of acute myelogenous leukemia: a randomized trial by the European Organization for Research and Treatment of Cancer Leukemia Cooperative Group. J Clin Oncol 1996; 14: 2150–2159.

    Article  CAS  PubMed  Google Scholar 

  33. He X-Y, Elson P, Pohlman B, Lichtin A, Hussein M, Andresen S et al. Timed sequential chemotherapy with concomitant granulocyte-colony stimulating factor for high-risk acute myelogenous leukemia: a single arm clinical trial. BMC Cancer 2002; 2: 12.

    Article  PubMed  PubMed Central  Google Scholar 

  34. Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DAG, Granlnick HR et al. Proposed revised criteria for the classification of acute myeloid leukemia. Ann Intern Med 1985; 103: 626–629.

    Article  Google Scholar 

  35. Kalaycio M . Inpatient management of acute leukemia. Cleveland Clin J Med 1997; 64: 385–389.

    Article  CAS  Google Scholar 

  36. Ajani JA, Welch SR, Raber MN, Fields WS, Krakoff IH . Comprehensive criteria for assessing therapy-induced toxicity. Cancer Invest 1990; 8: 147–159.

    Article  CAS  PubMed  Google Scholar 

  37. Kaplan EL, Meier P . Nonparametric estimation of incomplete observations. J Am Stat Assoc 1958; 53: 457–481.

    Article  Google Scholar 

  38. Ohno R, Naoe T, Kanamaru A, Yoshida M, Hiraoka A, Kobayashi T, Ueda T et al. A double-blind controlled study of granulocyte colony-stimulating factor started two days before induction chemotherapy in refractory acute myeloid leukemia. Kohseisho Leukemia Study Group. Blood 1994; 83: 2086–2092.

    CAS  PubMed  Google Scholar 

  39. Estey E, Thall P, Andreeff M, Beran M, Kantarjian H, O'Brien S et al. Use of granulocyte colony-stimulating factor before, during, and after fludarabine plus cytarabine induction therapy of newly diagnosed acute myelogenous leukemia or myelodysplastic syndromes: comparison with fludarabine plus cytarabine without granulocyte colony-stimulating factor. J Clin Oncol 1994; 12: 671–678.

    Article  CAS  PubMed  Google Scholar 

  40. Archimbaud E, Fenaux P, Reifferes J, Cordonnier C, Leblond V, Travade P et al. Granulocyte-macrophage colony-stimulating factor in association to timed-sequential chemotherapy with mitoxantrone, etoposide, and cytarabine for refractory acute myelogenous leukemia. Leukemia 1993; 7: 372–377.

    CAS  PubMed  Google Scholar 

  41. Thomas X, Fenaux P, Dombret H, Delair S, Dreyfus F, Tilly H et al. Granulocyte–macrophage colony-stimulating factor (GM-CSF) to increase efficacy of intensive sequential chemotherapy with etoposide mitoxantrone and cytarabine (EMA) in previously treated acute myeloid leukemia: a multicenter randomized placebo-controlled trial (EMA91 Trial). Leukemia 1999; 13: 1214–1220.

    Article  CAS  PubMed  Google Scholar 

  42. Mitus AJ, Miller KB, Schenkein DP, Ryan HF, Parsons SK, Wheeler C et al. Improved survival for patients with acute myelogenous leukemia. J Clin Oncol 1995; 13: 560–569.

    Article  CAS  PubMed  Google Scholar 

  43. Berman E, Heller G, Santorsa J, McKenzie S, Gee T, Kempin S et al. Results of a randomized trial comparing idarubicin and cytosine arabinoside with daunorubicin and cytosine arabinoside in adult patients with newly diagnosed acute myelogenous leukemia. Blood 1991; 15: 1666–1674.

    Google Scholar 

  44. Wiernik PH, Banks PL, Case Jr DC, Arlin ZA, Periman PO, Todd MB et al. Cytarabine plus idarubicin or daunorubicin as induction and consolidation therapy for previously untreated adult patients with acute myeloid leukemia. Blood 1992; 15: 313–319.

    Google Scholar 

  45. Vogler WR, Velez-Garcia E, Weiner RS, Flaum MA, Bartolucci AA, Omura GA et al. A phase III trial comparing idarubicin and daunorubicin in combination with cytarabine in acute myelogenous leukemia: a Southeastern Cancer Study Group Study. J Clin Oncol 1992; 10: 1103–1111.

    Article  CAS  PubMed  Google Scholar 

  46. Mandelli F, Petti MC, Ardia A, Di Pietro N, Di Raimondo F, Ganzina F et al. A randomised clinical trial comparing idarubicin and cytarabine to daunorubicin and cytarabine in the treatment of acute non-lymphoid leukaemia. A multicentric study from the Italian Co-operative Group GIMEMA. Eur J Cancer 1991; 27: 750–755.

    Article  CAS  PubMed  Google Scholar 

  47. Rees JKH, Gray RG, Wheatley K . Dose intensification in acute myeloid leukemia: greater effectiveness at lower cost. Principle report of the Medical Research Council's AML9 study. Br J Haematol 1996; 94: 89–98.

    Article  CAS  PubMed  Google Scholar 

  48. Weick JK, Kopecky KJ, Appelbaum FR, Head DR, Kinsbury LL, Balcerzak SP et al. A randomized investigation of high-dose versus standard-dose cytosine arabinoside with daunorubincin in patients with previously untreated acute myeloid leukemia: a Southwest Oncology Group study. Blood 1996; 88: 2841–2851.

    CAS  PubMed  Google Scholar 

  49. Bishop JF, Matthews JP, Young GA, Szer J, Gillett A, Joshua D et al. A randomized study of high-dose cytarabine in induction in acute myeloid leukemia. Blood 1996; 87: 1710–1717.

    CAS  PubMed  Google Scholar 

  50. Schiller G, Gajewski J, Nimer S, Territo M, Ho W, Lee Myung et al. A randomized study of intermediate versus conventional-dose cytarabine as intensive induction for acute myelogenous leukemia. Br J Haematol 1992; 81: 170–177.

    Article  CAS  PubMed  Google Scholar 

  51. Buchner T, Urbanitz D, Hiddemann W, Ruhl H, Ludwig WD, Fischer J et al. Intensified induction and consolidation with and without maintenance chemotherapy for acute myeloid leukemia (AML): two multicenter studies of the German AML Cooperative Group. J Clin Oncol 1985; 3: 1583–1589.

    Article  CAS  PubMed  Google Scholar 

  52. Buchner T, Hiddemann W, Wormann B, Loffler H, Gassmann W, Haferlach T et al. Double induction strategy for acute myeloid leukemia: the effect of high-dose cytarabine with daunorubicin and 6-thioguanine: a randomized trial by the German AML Cooperative Group. Blood 1999; 93: 4116–4124.

    CAS  PubMed  Google Scholar 

  53. Hiddemann W, Buchner T . Current status and perspectives of therapy for acute myeloid leukemia. Semin Hematol 2001; 38 (Suppl 6): 3–9.

    Article  CAS  PubMed  Google Scholar 

  54. Bishop JF, Lowenthal PM, Joshua D, Matthews JP, Todd D, Cobcroft R et al. Etoposide in acute non-lymphocytic leukemia. Blood 1990; 75: 27–32.

    CAS  PubMed  Google Scholar 

  55. Hann IM, Stevens RF, Goldstone AH, Rees JK, Wheatley K, Gray RG et al. Randomized comparison of DAT versus ADE as induction chemotherapy in children and younger adults with acute myeloid leukemia. Results of the Medical Research Council's 10th AML trial (MRC AML 10). Blood 1997; 89: 2311–2308.

  56. Hwang WL, Young JH, Gau JP, Hu HT, Tsai YT . DAE (daunorubicin, Ara-C, and etoposide) and intermediate dose Ara-C for remission induction and consolidation treatment of adult patients with acute myeloid leukemia. Am J Clin Oncol 1992; 15: 531–534.

    Article  CAS  PubMed  Google Scholar 

  57. Woods WG, Kobrinsky AJM, Miller KB, Schenkein DP, Ryan HF, Parsons SK et al. Improved survival for patients acute myelogenous leukemia. J Clin Oncol 1995; 13: 560–569.

    Article  Google Scholar 

  58. Loeb DM, Bowers DC, Civin CI, Friedman AD . Intensive timed sequential remission induction chemotherapy with high-dose cytarabine for childhood acute myeloid leukemia. Med Pediatr Oncol 2001; 37: 365–371.

    Article  CAS  PubMed  Google Scholar 

  59. Mrozek K, Heinonen K, de la Chapelle A, Bloomfield CD . Clinical significance of cytogenetics in acute myeloid leukemia. Semin Oncol 1997; 24: 17–31.

    CAS  PubMed  Google Scholar 

  60. Grimwade D, Walker H, Oliver F, Wheatley K, Harrison C, Harrison G et al. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1612 patients entered into the MRC AML 10 trial. Blood 1998; 92: 2322–2333.

    CAS  PubMed  Google Scholar 

  61. Stein AS, O'Donnell MR, Slovak KL, Nademanee A, Dagis A, Schmidt GM et al. High-dose cytosine arabinoside and daunorubicin induction therapy for adult patients with de novo non M3 acute myelogenous leukemia: impact of cytogenetics on achieving a complete remission. Leukemia 2000; 14: 1191–1196.

    Article  CAS  PubMed  Google Scholar 

  62. Mayer RJ, David RB, Schiffer CA, Berg DT, Powell BL, Schulman P et al. Intensive postremission chemotherapy in adults with acute myeloid leukemia. N Engl J Med 1994; 331: 896–903.

    Article  CAS  PubMed  Google Scholar 

  63. Bloomfield CD, Lawrence D, Byrd JC, Carroll A, Pettenati MJ, Tantravahi R et al. Frequency of prolonged remission duration after high-dose cytarabine intensification in acute myeloid leukemia varies by cytogenetic subtypes. Cancer Res 1998; 58: 4173–4179.

    CAS  PubMed  Google Scholar 

  64. Jahns-Streubel G, Braess J, Schoch C, Schoch C, Fonatsch C, Haase D et al. Cytogenetic subgroups in acute myeloid leukemia differ in proliferating activity and response to GM-CSF. Leukemia 2001; 15: 377–384.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

We are indebted to the nurses and staff of H71 Nursing Station at the Cleveland Clinic Foundation. This study would not be possible without their support.

Author information

Authors and Affiliations

  1. Department of Hematology and Medical Oncology, Cleveland, OH, USA

    X-Y He, B Pohlman, A Lichtin & M Kalaycio

  2. Department of Biostatistics, The Cleveland Clinic Foundation, Cleveland, OH, USA

    L Rybicki

Authors
  1. X-Y He
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. B Pohlman
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. A Lichtin
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. L Rybicki
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. M Kalaycio
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

He, XY., Pohlman, B., Lichtin, A. et al. Timed-sequential chemotherapy with concomitant granulocyte colony-stimulating factor for newly diagnosed de novo acute myelogenous leukemia. Leukemia 17, 1078–1084 (2003). https://doi.org/10.1038/sj.leu.2402955

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.leu.2402955

Keywords

This article is cited by

Search

Advanced search

Quick links